Distribution of cardiovascular drugs among the study patients (on discharge).

<p>Distribution of cardiovascular drugs among the study patients (on discharge).</p

Baseline characteristics and co-morbidities of the study population.

<p>Data are number (%) of patients or mean ± SD.</p><p>CRF - chronic renal failure, PVD - peripheral vascular disease.</p

Outcomes of the study population during follow-up (crude data).

<p>Data are number of events/(%).</p><p>- The primary endpoint of this study was 30-day Major Adverse Coronary Events (MACE): all-cause mortality, recurrent MI, recurrent ischemia, stent thrombosis, ischemic stroke, urgent revascularization during follow-up.</p

Rate (%) of 30-day Major Adverse Coronary Events (MACE) among the study patients according to the age, gender, level of HDL cholesterol, triglycerides, smoking status, presence of diabetes and hypertension.

<p>Rate (%) of 30-day Major Adverse Coronary Events (MACE) among the study patients according to the age, gender, level of HDL cholesterol, triglycerides, smoking status, presence of diabetes and hypertension.</p

Effect of combined fibrate/statin treatment vs. statin monoterapy on 30-day Major Adverse Coronary Events (MACE) in risk subgroups: odds ratio and 95% confidence interval (CI).

<p>HDL-C - high density lipoproteins cholesterol.</p

The applied model of multivariable logistic regression analysis of risk for 30-day MACE in patients immediately post acute coronary syndrome.

<p>The applied model of multivariable logistic regression analysis of risk for 30-day MACE in patients immediately post acute coronary syndrome.</p

Kaplan-Meier curve of mortality rate during one year follow-up for 7243 patients from years 2000–2008 (combined fibrate/statin therapy vs. statin monotherapy, p log-rank = 0.066).

<p>Kaplan-Meier curve of mortality rate during one year follow-up for 7243 patients from years 2000–2008 (combined fibrate/statin therapy vs. statin monotherapy, p log-rank = 0.066).</p